Twitter Facebook Linked In Zone In Google Plus 
January 2019 Research Update

Conquering Irritable Bowel Disease by Targeting Leukocytes

As recently reported in Nature Communications, scientists from Tel Aviv University have used targeted expression of interleukin 10 (IL-10) mRNA in Ly6c+ inflammatory leukocytes to bring new hope to people suffering from irritable bowel disease (IBD).

This is the first in vivo delivery system targeting leukocytes that has resulted in selective and efficient mRNA-based protein expression.

IBD refers to a group of intestinal disorders, including Crohn's disease and ulcerative colitis. These disorders are characterized by a complex and dysregulated immune response and are associated with an imbalance of the intestinal microbiota, resulting in chronic inflammation of the intestinal tract.

To combat this, the authors focused on increasing IL-10 expression, an important anti-inflammatory cytokine involved in balancing intestinal immunity. However, they also acknowledge that past clinical trials using recombinant IL-10 have failed to induce a robust therapeutic effect.

"The main hurdles with recombinant IL-10 treatment were the short half-life of only a few hours and the high protein concentration needed for systemic administration, which resulted in increased toxicity," the authors explain....

Read More
Bioconjugation Services
Using Chromalink® technology, our team of bioconjugation experts can perform custom conjugations to any biomolecule, including antibodies, oligos, proteins, peptides, aptamers, and even solid surfaces and magnetic beads.
mRNA with Modifications and Scales that Work for You!
Our portfolio of catalog and custom synthesis mRNA is available with our CleanCap® Technology - which achieves superior translation and is avaliable with a wide array of modifications at scales ranging from micrograms to grams.
Get instant pricing for modified and standard oligos up to 15 µmole synthesis scale.

Oligonucleotide and Peptide

Join Us

The 11th Annual Asia TIDES Conference. A global oligonucleotide and peptide forum for industry leaders to gather and share the latest groundbreaking science.

Meet Us: Please contact us at to schedule a meeting at Asia TIDES or feel free to stop by Booth #15 to speak to our technical experts!

Location: Hilton Tokyo Bay Hotel, Tokyo, Japan

Date: February 26-28, 2019

Hope to see you there!

Ask An Expert

Are the Requirements for Using CleanCap mRNA Different Than ARCA mRNA?

The requirements for using CleanCap mRNA are no different than using ARCA mRNA. You can use your standard electroporation or transfection conditions. There are several advantages with using a CleanCap mRNA. The translational efficiency far exceeds that of a standard ARCA capped mRNA...

Read More
Zone In With The Zon Blog Post

A Comprehensive Landscape of Transcription Errors in Cells

Biological reactions are remarkably precise. For example, enzymatic proteins have the amazing ability to not only selectively bind to only the correct substrates from among complex mixtures of countless molecules, but also to do so at the right time and location. This precision is especially important in the context of DNA replication...

View Blog Post


© 2019 TriLink BioTechnologies | All Rights Reserved